Cited 0 times in Scipus Cited Count

A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.

DC Field Value Language
dc.contributor.authorChoi, JH-
dc.contributor.authorLee, BH-
dc.contributor.authorKo, JM-
dc.contributor.authorSohn, YB-
dc.contributor.authorLee, JS-
dc.contributor.authorKim, GH-
dc.contributor.authorHeo, SH-
dc.contributor.authorPark, JY-
dc.contributor.authorKim, YM-
dc.contributor.authorKim, JH-
dc.contributor.authorYoo, HW-
dc.date.accessioned2017-04-25T06:11:09Z-
dc.date.available2017-04-25T06:11:09Z-
dc.date.issued2015-
dc.identifier.issn1011-8934-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13916-
dc.description.abstractGaucher disease is a lysosomal storage disease for which enzyme replacement therapy has proven to be effective. A switch-over clinical trial was performed to evaluate the efficacy and safety of Abcertin® (ISU Abxis, Seoul, Korea) in subjects with type 1 Gaucher disease who were previously treated with imiglucerase. Five Korean patients with type 1 Gaucher disease were enrolled. Previous doses of imiglucerase ranged from 30 to 55 U/kg every other week. The same dose of Abcertin® was administered to all patients for 24 weeks. Primary efficacy endpoints were changes in hemoglobin levels and platelet counts, and the secondary efficacy endpoints included changes in liver and spleen volumes, serum biomarkers, skeletal status and bone mineral density (BMD). During the study period, no statistically significant changes were observed in all parameters including hemoglobin levels and platelet counts, liver and spleen volumes, skeletal status and BMD. Abcertin® administration was continued in three patients for another 24 weeks as an extension of the study. Hemoglobin levels and platelet counts were maintained in all three patients. In conclusion, the efficacy and safety of Abcertin® are similar to those of imiglucerase, and Abcertin® is an effective therapeutic agent for patients with type 1 Gaucher disease (Clinical Trial Registry No. NCT02053896 at www.clinicaltrials.gov).-
dc.language.isoen-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHBiosimilar Pharmaceuticals-
dc.subject.MESHChild-
dc.subject.MESHEnzyme Replacement Therapy-
dc.subject.MESHFemale-
dc.subject.MESHGaucher Disease-
dc.subject.MESHGlucosylceramidase-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHRecombinant Proteins-
dc.titleA phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.-
dc.typeArticle-
dc.identifier.pmid25829804-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366957/-
dc.contributor.affiliatedAuthor손, 영배-
dc.type.localJournal Papers-
dc.identifier.doi10.3346/jkms.2015.30.4.378-
dc.citation.titleJournal of Korean medical science-
dc.citation.volume30-
dc.citation.number4-
dc.citation.date2015-
dc.citation.startPage378-
dc.citation.endPage384-
dc.identifier.bibliographicCitationJournal of Korean medical science, 30(4). : 378-384, 2015-
dc.identifier.eissn1598-6357-
dc.relation.journalidJ010118934-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Genetics
Files in This Item:
25829804.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse